ARKRAY USA

MINNEAPOLIS, October 1, 2020 (PR NEWSWIRE) – ARKRAY USA, Inc., a leader in diabetes care products, announces the Company’s TechLITE Pen Needles are now indicated for use with pen injector devices for the subcutaneous injection of drugs. Previously, TechLITE Pen Needles were intended for the use of insulin only.

“ARKRAY’s customers and the patients we serve will benefit from the expanded indication of the TechLITE Pen Needles,” said ARKRAY Vice-President of Consumer Healthcare, Robert Wernsman. “We’ve received tremendous market acceptance of TechLITE Pen Needles since we launched this product line in 2016 and we expect greater acceptance now given the expanded indications.”

TechLITE Pen Needles combine thin-wall technology with precise lubrication techniques and pinpoint sharpening to provide a safe and precise injection experience and are available in multiple gauges to meet individual needs.